The Swedish Drug Discovery and Development Pipeline Report 2023 contains a mapping of the pharmaceutical pipeline run by companies headquartered in Sweden.
The target group for the report includes international investors, the life science industry in Sweden and of course decision makers within politics, business and academia. The aim of the report is to provide a basis for fact-based improvements of the industry and to promote Sweden’s position in pharmaceutical development.
Register for the live broadcast of the launch
You can register in advance to the live broadcast of the report launch on March 8 at 14:00 CEST. Tune in for key findings in the Swedish Drug Discovery and Development Pipeline Report 2023. We’ll be broadcasting from the studio of our member and launch partner, DNB.
Dr Maja Neiman, report editor and Science Relations Manager at SwedenBIO, will give a seminar focused on key findings from the report, alongside Daniel Chancellor, Thought Leadership and Consulting Director at Citeline. SwedenBIO’s Director of Communications and International Marketing Alexandra Hoegberg is moderating.
You are welcome to submit questions during the broadcast.
Access the Report
On March 8, the report will be available to download free-of-charge on www.swedenbio.se/reports. In the report package, you will be able to access:
- The report: Including data visualisations of key findings, feature articles, columns, highlights, and a methodology section.
- The report appendix: The full lists of all 506 projects from the 159 companies covered in the report.
- Company list 2023: An excel file that you can sort as you wish.
- Project list 2023: An excel file that you can sort as you wish.